Relationship between total serum IgG concentration and tumor progression in patients with gastric cancer

doi:10.3760/cma.j.issn.1673-422X.2018.03.007

Abstract

Abstract: Objective To investigate the relationship between total serum IgG concentration and tumor progression in patients with gastric cancer. Methods From January 2010 to May 2017, a total of 90 patients with gastric cancer in Sun Simiao Hospital of Beijing University of Chinese Medicine were enrolled as study subjects and 90 ageandsex-matched adults from normal physical examination were enrolled as control subjects. The serum IgG subgroup and total IgG concentrations were measured by enzymelinked immunosorbent assay. The relationships between serum IgG concentration in patients with gastric cancer and clinicopathologic features were analyzed. The numbers of plasma cells with CD138 antibody in both tumor and non-cancerous tissues were evaluated by immunohistochemistry. Results The total serum IgG concentration in patients with gastric cancer was significantly lower than that in healthy control group ［(923.6±290.5) mg/dl vs. (1072.5±298.6) mg/dl］, with a significant difference (t=3.391, P=0.001). The total serum IgG and IgG1 concentrations were correlated with lymphatic metastasis (t=3.585, P<0.001; t=3.545, P<0.001) and gastric cancer stages (t=3.669, P<0.001; t=3.401, P<0.001). Furthermore, the CD138+ plasma cells in tumor tissues were significantly fewer than those in noncancerous gastric mucosa (88.7±31.9 vs. 108.5±33.4), with significant differences (t=2.778, P=0.007). Multivariate analysis suggested that total serum IgG concentration (HR=0.411, 95%CI: 0.0940.989, P=0.011) and lymph node metastasis (HR=3.148, 95%CI: 1.9885.297, P<0.001) were independent predictors for poor prognosis. Conclusion Decreased total serum IgG concentration is closely related to tumor progression and poor prognosis in patients with gastric cancer, which indicates that the impaired humoral immunity is associated with tumor progression.

Key words: Stomach neoplasms, Immunoglobulin G, Plasma cells, Immunity, Prognosis

Wei Tiejun, Guo Yijing, Zhang Yongli, Jiang Meng, Zhang Heng. Relationship between total serum IgG concentration and tumor progression in patients with gastric cancer[J]. Journal of International Oncology, 2018, 45(3): 157-160.

References

［1］ Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016［J］. CA Cancer J Clin, 2016, 66(1): 7-30. DOI: 10.3322/caac.21332. ［2］宋杰, 陈凤格, 赵伟, 等. 胃癌的发病率现状与治疗研究进展［J］. 中国慢性病预防与控制, 2016, 24(9): 704707. DOI: 10.16386/j.cjpccd.issn.1004-6194.2016.09.019. ［3］ Finn OJ. Cancer immunology［J］. N Engl J Med, 2008, 358(25): 2704-2715. DOI: 10.1056/NEJMra072739. ［4］郭振红, 曹雪涛. 肿瘤免疫细胞治疗的现状及展望［J］. 中国肿瘤生物治疗杂志, 2016, 23(2): 149-160. DOI: 10.3872/j.issn.1007-385X.2016.02.001. ［5］张百红, 岳红云. 免疫微环境促进肿瘤发生发展的机制研究进展［J］. 现代肿瘤医学, 2015, 23(6): 862-864. DOI: 10.3969/j.issn.1672-4992.2015.06.38. ［6］ Li Q, TeitzTennenbaum S, Donald EJ, et al. In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy［J］. J Immunol, 2009, 183(5): 3195-3203. DOI: 10.4049/jimmunol.0803773. ［7］ Layke JC, Lopez PP. 胃癌: 诊断和治疗方案的选择［J］. 中国全科医学, 2015, 18(3): 248249. DOI: 10.3969/j.issn.10079572.2015.03.003. ［8］ Huber V, Camisaschi C, Berzi A, et al. Cancer acidity: an ultimate frontier of tumor immune escape and a novel target of immunomodulation［J］. Semin Cancer Biol, 2017, 43: 74-89. DOI: 10.1016/j.semcancer.2017.03.001. ［9］ Kohrt HE, Tumeh PC, Benson D, et al. Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immunooncology clinical trials［J］. J Immunother Cancer, 2016, 4: 15. DOI: 10.1186/s40425-016-0118-0. ［10］沈梦, 任秀宝. B淋巴细胞参与肿瘤免疫抑制机制的研究进展［J］. 中国肿瘤生物治疗杂志, 2016, 23(1): 135-139. DOI: 10.3872/j.issn.1007-385X.2016.01.023. ［11］ Karagiannis P, Gilbert AE, Josephs DH, et al. IgG4 subclass antibodies impair antitumor immunity in melanoma［J］. J Clin Invest, 2013, 123(4): 1457-1474. DOI: 10.1172/JCI65579. ［12］ Mizukami M, Hanagiri T, Shigematsu Y, et al. Effect of IgG produced by tumorinfiltrating B lymphocytes on lung tumor growth［J］. Anticancer Res, 2006, 26(3A): 1827-1831. ［13］ Jefferis R, Kumararatne DS. Selective IgG subclass deficiency: quantification and clinical relevance［J］. Clinical & Experimental Immunology, 1990, 81(3): 357-367. ［14］蔡晓珊, 朱洪光, 牛娜. 免疫球蛋白G在牙龈鳞状细胞癌中的表达［J］. 山东医药, 2013, 53(29): 4-6. DOI: 10.3969/j.issn.1002-266X.2013.29.002. ［15］朱颖蔚, 岑岭, 王梦洁. 胃癌患者血清血管内皮生长因子、组织多肽特异性抗原的表达及意义［J］. 实用临床医药杂志, 2015, 19(15): 174-175. DOI: 10.7619 /jcmp.201515059. ［16］ Storm L, Christensen IJ, Jensenius JC, et al. Evaluation of complement proteins as screening markers for colorectal cancer［J］. Cancer Immunol Immunother, 2015, 64(1): 41-50. DOI: 10.1007/s00262-014-1615-y. ［17］ Coronella JA, Spier C, Welch M, et al. Antigendriven oligoclonal expansion of tumorinfiltrating B cells in infiltrating ductal carcinoma of the breast［J］. J Immunol, 2002, 169(4): 1829-1836. ［18］ Guillem EB, Sampsel JW. Antitumorassociated antigens IgGs: dual positive and negative potential effects for cancer therapy［J］. Adv Exp Med Biol, 2006, 587: 341-374. ［19］ Inoue S, Leitner WW, Golding B, et al. Inhibitory effects of B cells on antitumor immunity［J］. Cancer Res, 2006, 66(15): 7741-7747. DOI: 10.1158/00085472.CAN-05-3766. ［20］ DiLillo DJ, Matsushita T, Tedder TF. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer［J］. Ann N Y Acad Sci, 2010, 1183: 38-57. DOI: 10.1111/j.1749-6632.2009.05137.x. ［21］ Nelson BH. CD20+ B cells: the other tumorinfiltrating lymphocytes［J］. J Immunol, 2010, 185(9): 4977-4982. DOI: 10.4049/jimmunol.1001323.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[5]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[6]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[7]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[8]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[9]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[10]	Xie Shuping, Sun Yahong, Wang Chao. Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 157-165.
[11]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[12]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[13]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[14]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[15]	Huang Zhen, Chen Yongshun. Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma [J]. Journal of International Oncology, 2024, 51(1): 59-64.